Pancreatic cancer could be treated with a Parkinson's drug

 

Bhutia Lab

A new study shows that a common drug for Parkinson's disease has anti-cancer effects in mice and human pancreatic cells.

The new research suggests that carbidopa, which is a drug approved by the Food and Drug Administration (FDA) and widely used to treat Parkinson's disease, has significant anti-cancer properties.

Carbidopa is typically used in conjunction with levodopa (L-Dopa) to treat Parkinson's disease. And previous studies have shown that patients with Parkinson's tend to have a lower incidence of cancer.

In older research, scientists investigated whether or not it was the drug L-Dopa that yielded the anti-cancer effect, but they did not find any significant results.

So now, a team led by Dr. Yangzom Bhutia - from the Texas Tech University Health Sciences Center (TTUHSC) in Lubbock - hypothesized that carbidopa alone could have anti-cancer properties.

Commenting on the motivation for the research, Dr. Bhutia says, "Interestingly, no one has previously suspected carbidopa as a potential player in this phenomenon."

"Carbidopa is never used by itself as a drug for any disease," she adds. "But [...] we believe that the reduced incidence of most cancers in Parkinson's disease patients is due to carbidopa."

The first author of the study is Jiro Ogura, of the Department of Cell Biology and Biochemistry at TTUHSC, and the findings were published in the Biochemical Journal.

Article originally published in Medical News Today, www.medicalnewstoday.com

To read full article, please visit https://www.medicalnewstoday.com/articles/319578.php

Related Stories

Noise-Induced Hearing Loss in Rural Adolescents

Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.

Willed Body Memorial Service Honors Those Who Donated

On Memorial Day each May, a service is conducted at the Texas Tech University Health Sciences Center Institute of Anatomical Sciences to pay respect to the Willed Body Program donors and their families.

Molecular Pathology Preceptorship: Unmatched Value and Experience

Ericka Hendrix, PhD, MB(ASCP)CM, Program Director and Associate Professor in the Master of Science in Molecular Pathology program in the School of Health Professions spoke about the program’s preceptorship.

Recent Stories

Health

TTUHSC Receives $1.3 Million HRSA Telehealth Resource Center Grant to Expand Telehealth in Texas and Louisiana

The TexLa Telehealth Resource Center, based at TTUHSC, has been awarded a $1.3 million, four-year grant from HRSA to strengthen and expand digital health services in Texas and Louisiana.

Health

The Relational Health Center Celebrates Two Years of Care for Families

On Friday, August 22, from 3 - 5 p.m., the Relational Health Center is celebrating its second birthday with an open house event at Covenant Children’s Hospital in Lubbock.

Campus Life

From Backpacks to White Coats: TTUHSC School of Medicine Invests in Tomorrow’s Healers Today

As part of its partnership with JAMP, the TTUHSC School of Medicine Admissions Office recently partnered with Alderson Elementary School in the Lubbock Independent School District to provide critical school supplies.